Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChAd and SAM Prime-Boost Vaccines for SARS-CoV-2
NCT04776317Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Mar 2021
- Primary completion
- Sep 2023
- Modality
- Viral Vector Vaccines, Lipid-based Nanoparticles, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of ChAdV68-S, SAM-LNP-S and GRT-R912 in coronavirus disease 2019 (COVID-19) (13 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Frequency of Any New-onset Chronic Medical Conditions at 1 year, Frequency of Any Potentially Immune-mediated Medical Conditions at 1 year and 5 more. Started Mar 2021; status: completed.
02
Drugs
ChAdV68-SSAM-LNP-SGRT-R912
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04776317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04776317.